Previous 10 | Next 10 |
To be a shareholder of record, investors are advised to own Navidea Biopharmaceuticals stock by 4:00 PM ET, Monday, August 1, 2022 to account for T+2 settlement timing Record date established as Wednesday, August 3, 2022 Navidea Biopharmaceuticals, Inc. (NYSE America...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “Increased Mac...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today provided an informational update to stockholders regarding its propose...
Navidea Biopharmaceuticals ( NYSE: NAVB ) largest shareholder and Board Vice Chair John K. Scott, funded an additional $1M under the secured bridge loan that was executed on April 10, 2022 . “We are delighted to have the continued funding in place from Mr. ...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on July 1, 2022, its largest shareholder and Vice Chair...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract titled, “TAM Targeted Imag...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract titled, “CD206 Targeted De...
Navidea Biopharmaceuticals, Inc. (NAVB) Q1 2022 Results Conference Call May 12, 2022 5:00 PM ET Company Participants Michael Rosol - CMO Erika Eves - VP, Finance & Administration Conference Call Participants Michael Okunewitch - Maxim Group Presentation Operator Welcome to the Navidea Bio...
Navidea Biopharm press release (NYSE:NAVB): Q1 GAAP EPS of -$0.10. $1.2 million in cash and cash equivalents. For further details see: Navidea Biopharm GAAP EPS of -$0.10
Conference Call to be held Thursday, May 12, 2022 at 5:00 pm (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutic...
News, Short Squeeze, Breakout and More Instantly...
Navidea Biopharmaceuticals Inc. Company Name:
NAVB Stock Symbol:
NYSE Market:
Navidea Biopharmaceuticals Inc. Website:
Navidea Biopharmaceuticals , Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic a...
Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024 Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of pre...
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...